Skip Navigation

Search Results

A total of 23 matching records were found.

ETCTN10061
A Phase 1 Study of MK-3475 (pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors (NCI#10061)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10129
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors (ETCTN10129)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10170
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies (ETCTN10170)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

ETCTN10204
10204: A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17127
A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Protocol IT-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18106
A Phase 1/1b multicenter study to evaluate the humanized anti-CD 73 antibody, CPI-006, as a single agent, or in combination with Ciforadenant with Pembrolizumab, and with Ciforadenant plus pembrolizumab in adult subjects with advanced cancers (CPI-006-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18114
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors (CA030-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18115
A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors (ASTX727)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18144
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer (FLX475-02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J19123
A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (20190135)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1924
A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR). NeoRay (Clinical Trial Protocol: CAAA603A12101)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1956
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (CA043-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1989
J1989 - A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1994
J1994: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined with Nivolumab and Ipilimumab for Patients with Resected MMR-p Colorectal and Pancreatic Cancer.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J20120
A Phase I/II, First-In-Human, Multi-Part, OpenLabel, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications (DF1001-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2043
J2043 - Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J2076
Phase 1 and phase 2a, first-in-human study of DRP-104, a glutamine antagonist, in adult patients with advanced solid tumors (DRA-104-001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J2089
A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (LOXO-IDH-20002)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNA021502
A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

NCTNCOV2006
(NCICOVID) NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study. COVID-19 RELATED SUBMISSION

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

NCTNEAQ172
EAQ172: Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

NCTNGY022
NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

SIB2117
A Phase 1B/2, Open-Label, Randomized Platform Study Evaluating The Efficacy And Safety Of AB928-Based Treatment Combinations In Patients With Metastatic Colorectal Cancer

Sites: Sibley Memorial Hospital

back to top button